Alzheimer's disease (AD); however, little is known about the mechanisms by which they contribute to the pathological process. As synapse loss is observed at the earliest stage of AD, deciphering the impact of AD risk genes on synapse formation and maintenance is of great interest. In this paper, we report a microfluidic co-culture device that physically isolates synapses from pre-and postsynaptic neurons and chronically exposes them to toxic amyloid-beta (Aβ) peptides secreted by model cell lines overexpressing wild-type or mutated (V717I) amyloid precursor protein (APP). Co-culture with cells overexpressing mutated APP exposed the synapses of primary hippocampal neurons to Aβ 1-42 molecules at nanomolar concentrations and induced a significant decrease in synaptic connectivity, as evidenced by distance-based assignment of postsynaptic puncta to presynaptic puncta. Treating the cells with antibodies that target different forms of Aβ suggested that low molecular weight oligomers are the likely culprit. As proof of concept, we demonstrate that overexpression of Pyk2 -an AD risk gene involved in synaptic plasticity and shown to decrease in AD brains at gene expression and protein levels-selectively in postsynaptic neurons is protective against Aβ 1-42 -induced synaptotoxicity. In summary, our lab-on-a-chip device provides a physiologically-relevant model of AD-related synaptotoxicity, optimal for assessing the impact of risk genes in pre-and postsynaptic compartments.
Introduction
Alzheimer's disease (AD), the most common neurodegenerative disorder worldwide, is characterized by two types of brain lesions: (i) neurofibrillary degeneration due to the intracellular aggregation of abnormally hyperphosphorylated tau protein and (ii) amyloid plaques resulting from the extracellular accumulation of amyloid beta (Aβ) peptides (1) . Aβ peptides are generated by the cleavage of the transmembrane amyloid precursor protein (APP) and can have different residue lengths (2) . The discovery of mutations in the APP, PS1 and PS2 genes (coding for APP and presenilins 1 and 2) causing early-onset, autosomal-dominant forms of AD has profoundly influenced our understanding of the disease, and has placed Aβ peptides at the center of the pathophysiological process. According to the "amyloid cascade hypothesis", the accumulation of Aβ peptides is the triggering toxic condition that induces the development of neurofibrillary degeneration and thus neuronal death (3) .
Aβ species have been the principal focus of research (4) since Aβ 1-42 is more prone to oligomerize (5, 6) and oligomers of Aβ are more toxic than its monomeric or fibrillary forms, and other Aβ species (7) (8) (9) . Oligomeric Aβ 1-42 is in a dynamic equilibrium with the monomeric forms and fibrils, and has been proposed to be the main promoter of amyloid plaques (10) . Although the central role of the Aβ peptide burden as initially enunciated in this hypothesis is strongly debated, several lines of evidence indicate that Aβ peptides are still a key actor of the disease at least via their oligomeric forms. In particular, the Aβ oligomer toxicity has been linked with synapse dysregulation and loss (11) .
Synapse loss is a major pathological correlate of cognitive deficits in AD (12) and is observed at the earliest stage of the disease (13) . Several mechanisms have been proposed to explain Aβ-induced synaptotoxicity: (i) membrane-disrupting activity at high concentrations (14) ; (ii) deleterious pruning of synapses by microglia activation (15) ; (iii) direct interaction of oligomeric forms with postsynaptic receptors, such as ionotrophic or metabotropic glutamate receptors (16, 17) . In addition, the new genetic landscape of AD, resulting from the advent of the genome wide association studies (GWAS) (18, 19) , highlights synaptic (dys)regulation: several among the dozens of genes/loci identified to be associated with AD risk, e.g., BIN1, CD2AP, FERMT2 and PTK2B, have been shown to modulate synaptic functions in the physio-and/or pathophysiological contexts (20) (21) (22) (23) (24) . As a result, we recently proposed a genetically-driven synaptic failure hypothesis, based on the genetic and post-GWAS data (25) . In this context, Aβ toxicity is one of the elements involved in synapse failure and it may be driven by specific AD genetic risk factors.
However, assessing such an hypothesis requires a number of considerations to be taken into account: (i) most in vitro models of Aβ toxicity use synthetic Aβ oligomers at non-physiological concentrations, even though synthetic fibrils are structurally different from Aβ fibrils obtained from AD brains (26) ; (ii) only a few of the GWAS-defined genes have been analyzed in a (physiological and/or pathophysiological) synaptic context; (iii) GWAS-defined genes may have different effects when expressed in the pre-or postsynaptic neurons. For example, proline-rich tyrosine kinase 2 (Pyk2), product of AD risk gene PTK2B, directly interacts with postsynaptic scaffold proteins (27) , regulates dendritic spine morphology (20) , and is involved in synaptic plasticity through regulating postsynaptic NMDA receptors via activation of Src (28) . Recent studies based on AD mouse models linked Pyk2's effects to amyloid pathology, but reported contradictory data on whether lack of Pyk2 was detrimental or protective (23, 29) .
With this background, we have developed a microfluidic co-culture device, based on existing tricompartment designs that physically isolate synapses and provide exclusive access to pre-and postsynaptic neurons (30, 31) . This device permits not only the induction of synaptotoxicity via physiologically-relevant concentrations of Aβ molecules secreted by cells stably overexpressing human APP, but also the analysis of synaptic density as a function of over-or underexpression of genetic risk factors in pre-and/or postsynaptic neurons. In this paper, we characterized Aβ-induced synaptotoxicity in primary neurons upon co-culture with cells overexpressing mutated APP and assessed the impact of Pky2 overexpression in postsynaptic neurons, as a proof of concept. sonication in water bath (Branson; Emerson Electric; St. Louis, MO) for 10 min. The solution was aliquoted into microcentrifuge tubes, let to evaporate in a chemical fume hood, dried with SpeedVac system (Thermo Fisher Scientific, Waltham, MA) for 30 min, and stored as desiccated peptide at -80°C. To produce oligomers, lyophilized, hexafluoroisopropanol-treated aliquots of both peptides were resuspended in DMSO to reach 5 mM, mixed by pipetting, sonicated in water bath for 10 min, diluted to 100 µM in ice-cold D-PBS, followed by 30 s vortexing and 1 h incubation at 25°C. The solutions were aliquoted into microcentrifuge tubes and stored at -20°C for up to 4 weeks. Before adding to neurons, oligomeric peptide stocks were thawed, serial diluted to 100 nM in 2 % DMSO in PBS. Aβ 1-42 concentrations up to 1 µM are considered non-lethal (36, 37) .
Microfluidic device design and fabrication
The microfluidic co-culture device was designed based on a previous tricompartmental neuron culture device (38) . The device consists of a 300 μm wide, 7.4 mm long central channel flanked by two 750 μm wide, 3.6 mm long side channels. All three channels are ca. 100 µm high. The left side channel (termed presynaptic) and the central channel (termed synaptic) are interconnected via 4 µm high, 450 µm long parallel microchannels that narrow from an entry width of 10 μm to an exit width of 3 μm. The right side channel (termed postsynaptic) and the synaptic chamber are also interconnected via parallel microchannels with identical dimensions, except that they were 75 μm long. One end of the synaptic chamber bifurcates into two branches, one of which terminates in a triangular shape. This terminus is connected to a diamond-shaped coculture chamber (based on a previous design) (39) via 4 μm high, 10 μm wide, and 100 μm long parallel microchannels.
Master patterns were fabricated at the IEMN (Lille, France) via two-step photolithography (40) . Ca. 4 mm high polydimethysiloxane (PDMS) pads were replica molded. Access wells were punched at the termini of the central channel and the co-culture chamber, and of the side channels using 3 mm and 4 mm biopsy punches (Harris Unicore), respectively. The devices were permanently bonded to 24 mm × 50 mm glass coverslips (Menzel) via O 2 plasma (Diener, Ebhausen, Germany). Prior to cell culture, the devices were sterilized under UV light (Light Progress, Anghiari, Italy) for 30min, treated with 0.1 mg/mL PLL overnight, and rinsed with PBS.
Primary neuron culture
Culture media and supplements were from Thermo Fisher, unless mentioned otherwise. Primary neurons were obtained from P0 rats, according to previously described procedures (41) . Briefly, cortices and hippocampi were isolated from new-born rats, washed with ice-cold dissection medium (HBSS supplemented with HEPES, sodium pyruvate, and penicillin/streptomycin), and trypsinized (2.5%; at 37°C for 10 min). Trypsin was inactivated with dissociation medium -MEM supplemented with fetal bovine serum (FBS), Glutamax, D-glucose (Sigma), MEM vitamins, and Pen/Strep-followed by DNase (5 mg/ml; Sigma) incubation for 1 min and wash with dissection medium. Media was replaced by dissociation medium and tissue was triturated with a fire-polished cotton-plugged Pasteur pipette to obtain a homogenous cell suspension, followed by centrifugation (200× g for 5 min). Cells were resuspended in culture medium (Neurobasal A supplemented with Glutamax and B 27 neural supplement with antioxidants), counted, and plated at a density of 100,000 cells/cm 2 in 6-and 24-well plates for immunoblots and in 10 cm Petri dishes for synaptosome extraction. Plates were pre-coated with 0.1 mg/mL poly-l-lysine (Sigma) in 0.1M borate buffer (0.31% boric acid, 0.475% sodium tetraborate, pH = 8.5; Sigma) overnight at 37°C and rinsed thoroughly with water. Alternatively, cells were plated in pre-coated 384-well plates at 50,000 cells/cm² (ca. 4,000 cells/well) and in microfluidic devices at a density of ca. 8×10 5 cells/cm 2 . After 20-24 h, culture media was replaced with supplemented Neurobasal A medium. 0.1% ethylenediaminetetraacetic acid (EDTA; in H 2 O) was added to the Petri dishes containing microfluidic devices to minimize evaporation. Cultures were maintained in a tissue culture incubator (Panasonic; Osaka, Japan) at 37°C and 5% CO 2 .
Immunoblotting
Neurons were harvested in minimum volume of 200 μl/well in 6-well plates, in ice-cold lysis buffer as described earlier (42) . Lysates were mixed with 4× LDS sample buffer (Novex; Thermo Fisher) and 10× reducing agent (Novex), sonicated, and boiled at 95°C for 10 min. Samples were loaded at maximum volume into 1.5 mm, 10-well, 4-12% Bis-Tris pre-cast NuPage gels (Novex), along with 5 μl MW marker (Novex Sharp pre-stained protein standard, Thermo Fisher). The gel was run with 2-(N-morpholino)ethanesulfonic acid (MES) running buffer at 200 V for 45 min and transferred to 0.22 μm nitrocellulose membranes using the Trans-Blot Turbo transfer system (BioRad, Hercules, CA) using mixed MW method at 1.3 A and 25 V for 7 min. Membranes were blocked in TNT (0.05% Tween 20, 20 mM Tris-Base, 150 mM NaCl, pH = 8.0) containing 5% non-fat dry milk for 1 h at RT and washed 3× in TNT. Membranes were incubated with the following primary antibodies in SuperBlock T20 blocking buffer (Thermo Scientific) at 4°C overnight and washed 3× in TNT: rabbit anti-phospho-PTK2B (Cell Signaling Technology 3291; 1/1,000; Danvers, MA), rabbit anti-PTK2B (Sigma P3902; 1/1,000), and mouse anti-β-actin (Sigma A1978; 1/5,000). Membranes were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (HRP-anti-Mouse and HRP-anti-rabbit; 1:5,000; Jackson ImmunoResearch, West Grove, PA) in TNT containing 5% non-fat dry milk for 1 h at RT and washed 3× in TNT. The membrane was revealed through chemiluminescence (Luminata Classico, EMD Merck Millipore) and imaged with Amersham Imager 600 (GE Healthcare, Mississauga, Canada). The images were quantified with ImageQuantTL Software (GE Healthcare).
Culture of CHO cells and analysis of their media
CHO cell lines (CHO-pcDNA4, -APP WT and -APP LDN ) were maintained according to previously described procedures (43) . Cells were grown in CHO growth medium: DMEM/Ham's F-12 1:1 medium, supplemented with 10% heat-inactivated FBS, 0.2% Pen/Strep, 2% HT supplement, and 300 µM Proline (Sigma). To stimulate Aβ production, the growth medium was replaced with CHO-NBA medium: phenol red-free Neurobasal A (Gibco) supplemented with 0.2% Pen/Strep, 2% HT supplement, and 300 µM Proline.
For media collection, cells were grown in 10 cm Petri dishes or in 6-well plates until they reached 80% confluence, at which point the maintenance medium was rinsed with PBS and replaced with the stimulation medium. After 48 h of stimulation, the medium was collected into 15 mL Falcon tubes and centrifuged at 4,000× g and 4°C for 10 min to remove the debris. The supernatant was loaded into a 3 kDa spin column (Amicon Ultra; Merck), equilibrated with Neurobasal (without serum or Phenol Red) at 4,000× g and 4°C for 10 min, and concentrated at 4,000× g and 4°C for 1 h. Western blotting of conditioned media was performed as described with the following exceptions: the transferred membrane was boiled for 5 min in PBS and Luminata Crescendo (Millipore) was used as the HRP substrate. Anti-Aβ 1-42 (clone 6E10; 1:1000; Sigma) was used as primary antibody.
Exposure of neurons to conditioned media
Total protein concentration in the conditioned media collected from different CHO cell lines (CHO-pcDNA4, -APP WT and -APP LDN ) was assessed using the Pierce BCA Protein Assay Kit (Thermo Fisher) and adjusted to 100 µg/µL with supplemented CHO-NBA medium. 10 µL of conditioned media (per well) was added to primary neuronal cultures grown in 384-well plates (containing 40 µL of culture medium per well) at DIV14, DIV18, DIV19, DIV20, and DIV21 (6 h prior to media collection). Media from these wells (8 wells per condition) were collected into a new 384-well plate prior to quantification of Aβ peptides.
Co-culture of neurons with CHO cells
CHO cells were seeded in the co-culture chamber at a density of ca. 1.3×10 5 cells/cm 2 and maintained in a tissue culture incubator (5% CO 2 ; 37°C) in CHO medium. On the day of primary neuron culture, the medium was replaced with CHO-NBA medium supplemented with 1% Glutamax and 2% B 27 neural supplement with antioxidants. Primary neurons were seeded in the pre-and postsynaptic chambers. At DIV1, the medium in all wells was replaced with fresh supplemented CHO-NBA medium. Every 3-4 days, the medium in the access wells of the co-culture chamber was replaced with fresh medium, whereas the medium in other wells were only topped up with fresh medium.
Lentiviral transductions
At DIV7, neurons cultured in the postsynaptic chamber were transducted with lentiviruses according to established methods. (41) To avoid transduction of CHO cells and the neurons in the presynaptic chamber, a hydrostatic pressure gradient was formed across the microchannels separating synaptic and postsynaptic chambers. The following lentiviruses were used for transduction: Mission shRNA vectors (Sigma) pLenti6/Ubc/v5-DEST (Invitrogen, Carlsbad, CA) empty (Mock) or including human PTK2B cDNA sequences, synthesized via the GeneArt service (Thermo Fisher). LifeAct-Ruby (pLenti.PGK.LifeAct-Ruby.W; RRID: Addgene_51009) and LifeAct-GFP (pLenti.PGK.LifeAct-GFP.W; RRID: Addgene_51010) were kind gifts from Rusty Lansford. Viral transduction was performed at multiplicity of infection (MOI) of 4. Constructs were diluted in pre-warmed, supplemented CHO-NBA medium containing 2 μg/mL (5×) Polybrene (hexadimethrine bromide; Sigma). Media from pre-and postsynaptic wells were collected in a common tube. 25 µL, 15 µL, and 20 µL of the collected media were returned to each presynaptic, synaptic, and postsynaptic well, respectively. 10 µL of virus suspension was added to one of the postsynaptic wells. Neurons were incubated with viral particles for 6 h before the wells were topped up with the remainder of the collected media. Co-cultures were maintained as described earlier.
Alpha-LISA measurements
Alpha-LISA is a highly sensitive, quantitative assay based on biotinylated antibody bound to streptavidincoated donor beads and antibody-conjugated acceptor beads. In the presence of the analyte, the beads come into close proximity such that the excitation of the donor beads triggers a cascade of energy transfer in the acceptor beads, resulting in a sharp peak of light emission at 615 nm. We used Alpha-LISA kits specific to human Aβ 1-X and Aβ 1-42 (AL288C and AL276C, respectively; PerkinElmer, Waltham, MA) to measure the amount of Aβ 1-X and Aβ 1-42 in culture media. The human Aβ analyte standard was diluted in CHO-NBA medium. For the assay, we first added 5 µL of cell culture supernatant or standard solution into an Optiplate-96 microplate (PerkinElmer). We then added 5 µL of 10× mixture including acceptor beads and biotinylated antibody. Following incubation at RT for 60 min, we added 40 µL of 1.25× donor beads and incubated at RT for 60 min. We measured the fluorescence using an EnVision-Alpha Reader (PerkinElmer) at 680 nm excitation and 615 nm emission wavelengths. In experiments where conditioned media was added to primary neurons in 384-well plates, 2 µL of collected media was transferred to an Optiplate-384 (PerkinElmer) and Alpha-LISA was performed using reduced volumes: 2 µL of sample or standard, 2 µL of acceptor beads and biotinylated antibody mix, and 16 µL of donor beads.
ELISA measurements
The sandwich ELISA was performed according to the manufacturer's protocol. We used microtiter plates pre-coated with anti-human Aβ 35-40 antibody (clone 1A10; RE59781, IBL) and anti-human Aβ [38] [39] [40] [41] [42] (clone 1C3; RE59721, IBL) to detect Aβ 1-40 and Aβ X-42 , respectively. Plates were incubated overnight at 4°C with 100 µL cell culture supernatant or with standards. The bound antigen was detected by incubating the wells with 100 µL of 30× mixture containing the HRP-conjugated anti-human Aβ antibodies (clone 82E1 for Aβ and clone 12B2 for Aβ X-42 ) for 60 min at 4°C. Signal was revealed by incubating with the TMB substrate for 30 min at RT in the dark and stopping the enzymatic reaction with the TMB stop solution containing 1N H 2 SO 4 . Signal intensity was read immediately at 405 nm via a microplate reader (PowerWave XS2, BioTek Instruments, Winooski, VT).
Immunocytochemistry and microscopy
Co-cultures were fixed at DIV14 in PBS containing 4% paraformaldehyde for 20 min at RT and permeabilized with 0.3% (v/v) Triton X-100 in PBS for 5 min. After blocking in 5% (w/v) normal donkey serum, samples were incubated overnight at 4°C with the following antibodies: anti-MAP2 (188011; Synaptic Systems, Göttingen, Germany); anti-Homer (160006; Synaptic Systems) and anti-PYK2 phospho-Y402 (ab4800; Abcam, Cambridge, UK). Cells were rinsed with PBS and incubated with the following secondary antibodies for 2 h at RT: Dylight 405 Donkey anti-mouse (715-475-151; Jackson); AlexaFluor 647 donkey anti-rabbit (711-605-152; Jackson) and AlexaFluor 594 Donkey anti-chicken (703-585-155; Jackson). Cells were rinsed with PBS and incubated with mouse monoclonal anti-Synaptophysin 1 prelabeled with Oyster 488 (101011C2; Synaptic Systems) for 2 h at RT. Cells were rinsed with PBS and microfluidic devices were topped with 90% glycerol.
Samples were imaged with a LSM 880 confocal microscope (Zeiss, Oberkochen, Germany) equipped with a 63× 1.4 NA objective. Images were acquired at zoom 2 in z-stacks of 0.5 µm interval. Typically, 4 images were acquired per device from the synapse chamber near the postsynaptic chamber such the image contains multiple dendrites. Images were deconvoluted using AutoQuantX3 software (BitPlane, Zurich, Switzerland) for synaptic connectivity analysis.
In a subset of experiments, neurons were plated only in the presynaptic chamber, only in the postsynaptic chamber, or only in the synaptic chamber. Neurons were fixed and immunostained at DIV14 as described to reveal nuclei, GFAP (ABD95; Millipore) and β3-tubulin (MAB1637, Millipore). All chambers were imaged using a Zeiss AxioObserver Z1 epifluorescense microscope equipped with a Prime 95B Scientific CMOS (Photometrics, Tucson, AZ) camera and 32× objective. The integrated density (pixel values × area) of the β3-tubulin signal was quantified in all chambers, at a distance between 50 and 200 μm from the entries and exits of the microchannels. Neurite penetration rates for short and long microchannels (in the forward and reverse directions) were estimated by taking the ratio of the β3-tubulin integrated density signals obtained from the emitting and receiving chambers. The ratio between the penetration rates between forward and reverse directions was defined as the directionality ratio.
Quantification of synapse integrity
We developed an image analysis workflow based on image segmentation using Imaris software (BitPlane) and assignment of postsynaptic signals to the nearest presynaptic signal using a custom Matlab (Mathworks; Natick, MA) code. Briefly, signals obtained for pre-and postsynaptic structures were first segmented into distinct volumes using the surfaces function of Imaris in the batch mode that permits the same parameters to be applied to all images (Fig. S1A-S1D). Postsynaptic spots were then assigned to the nearest presynaptic spot (according to the distance between centers of mass) within a predefined cut-off distance (Fig. S1E ). We empirically determined the cut-off distance by testing a range on a large set of control cultures ( Fig. S1F -S1G). The average number and distance of such assignments and the fraction of pre-and postsynaptic signals without any assignments were used as output parameters. Note that a small fraction of control samples for CHO-APP WT and CHO-APP LDN co-cultures (2 devices each) do overlap in the data reported.
Analysis of phospo-Pyk2 signals relative to synapses
We extended the image analysis workflow to analyze the positions of phospho-Pyk2 (Tyr402) (p-Pyk2) puncta relative to the positions of identified synapses. Postsynaptic spots were first assigned to the nearest presynaptic spot as described. For each postsynaptic-to-presynaptic assignment, or "synapse", we defined the midpoint as being equidistant to pre-and postsynaptic puncta. We next defined pre-and postsynaptic zones, by spanning two right circular cones with 45° polar angle where the midpoint is the apex. We then associated p-Pyk2 puncta with the nearest "synapse" as long as it was within a pre-defined cut-off distance from the midpoint and categorized these associations as presynaptic, postsynaptic, or other (neither pre-nor postsynaptic). We then calculated the average number of p-Pyk2 puncta associated with each "synapse".
Synaptosome extraction
To verify the presence of proteins at the synaptic level we did a subcellular fractionation as previously described (44) . Briefly, cortical neurons were cultured in 10 cm Petri dishes as described (3.5-4.0 × 10 7 neurons per condition). At DIV13, neurons were exposed to CHO-APP WT or CHO-APP LDN media for 18 h (final Aβ 1-X concentration: 40 nM). At the end of this treatment, neurons were lysed, reconstituted in a solution (0.32 M sucrose and 10 mM HEPES, pH = 7.4), and centrifuged at 1,000× g for 10 min to remove nuclei and debris. The supernatant was centrifuged at 12,000× g for 20 min to remove the cytosolic fraction. The pellet was reconstituted in a second solution (4 mM HEPES, 1 mM EDTA, pH = 7.4) and was centrifuged 2× at 12,000× g for 20 min. The new pellet was reconstituted in a third solution (20 mM HEPES, 100 mM NaCl, 0.5% Triton X-100, pH = 7.2) for 1 h at 4°C and centrifuged at 12,000× g for 20 min. The supernatant collected corresponds to the non-postsynaptic density (PSD) fraction (Triton-soluble). The remaining pellet was reconstituted in a fourth solution (20 mM HEPES, 0.15 mM NaCl, 1% Triton X-100, 1% deoxycholicacid, 1% SDS, pH = 7.5) for 1 h at 4°C and was centrifuged at 10,000× g for 15 min to obtain a supernatant containing the PSD fraction (Triton-insoluble). The fractions obtained were then analyzed by WB.
Analysis of gene expression alterations in human brain samples
RNA sequencing (RNAseq) data from the Mount Sinai/JJ Peters VA Medical Center Brain Bank (MSBB) (45) , the ROSMAP database (46) , and the Mayo Clinic whole genome and transcriptome data (47) were downloaded from AMP-AD Knowledge Portal (48) according to the terms and conditions concerning the use of the data. Data were aligned using pseudoaligner Kallisto version 0.43.1 (49) using a pre-built index to align fastq files. Differential gene expression analysis was performed using DESeq2 (50) . First, a DESeq2 object was created using DESeqDataSetFromTximport function and rows with sum of all counts less than 10 were filtered out. Next, DESeq function was used with default parameters. Temporal cortex was analyzed in the Mayo Clinic dataset (82 AD cases and 78 healthy controls). Dorsolateral prefrontal cortex was analyzed in the ROSMAP dataset (222 AD cases and 201 controls). The following brain areas were analyzed in the MSBB dataset: Brodmann area (BA) 10, which corresponds to the anterior prefrontal cortex (105 AD cases and 71 controls); BA 22, which is part of the Wernicke's area in the superior temporal gyrus (98 AD cases and 61 controls); BA 36, which corresponds to the lateral perirhinal cortex (88 AD cases and 64 controls); and BA 44, which corresponds to the inferior frontal gyrus (90 AD cases and 63 controls).
Analysis of neuropathological human sample cohort
The brain samples were collected through a brain donation program dedicated to neurodegenerative dementias coordinated by the NeuroCEB Brain Bank Network. The informed consent for post-mortem examination and research studies was signed by the legal representative of each patient in patient's name, as allowed by the French law and approved by the local ethics committee and the brain bank has been officially authorized to provide samples to scientists (agreement AC-2013-1887). All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki declaration. The brain banks fulfill criteria from the French Law on biological resources including informed consent, ethics review committee and data protection (article L1243-4 du Code de la Santé publique, August 2007). The Neuro-CEB brain bank (BioResource Research Impact Factor number BB-0033-00011) has been declared to the Ministry of Research and Higher Education, as required by French law.
Assessment of AD-related neurofibrillary pathology (Braak stage) was performed according to published procedures (51) by analyzing post-mortem brain tissue samples of 27 individuals (Table S1 ) via immunohistochemistry using AT8 antibody, which detects hyperphosphorylated Tau (52) . Lysis buffer containing, trizma-base 20 mM; NaCl 150 mM; cOmplete Protease Inhibitor Cocktail 1X and 1% triton, was added to single pieces of whole brain tissue (∼100 mg) at a ratio of 5 μL per 1 mg of tissue. Brain samples were homogenized by beads beating using a precellys soft tissue CK14 2 mL (3 × 30 s at 6,500 rpm). The lysate was then centrifuged at 4,000 rpm for 15 min at 4°C. 50 µL from the supernatant was used for analysis. Protein quantification was performed using BCA protein assay. Total proteins (40 µg/lane) were separated on 4-12% Bis-Tris-polyacrylamide gel electrophoresis (NuPAGE; Thermo Scientific) under reducing conditions and subsequently blotted onto nitrocellulose membranes using iBlot 2 Dry Blotting System (Biorad). Primary antibodies against phospho-Pyk2 Tyr 402 (1:1000; Cell Signalling, cat. no. 3291), total Pyk2 (1:1000; Sigma, cat. no. P3902) and β-actin (1:5000; Abcam, cat. no. ab8226) were used for immunoblotting. After incubation with the appropriate HRP-conjugated secondary antibodies, the protein bands were detected using ImageJ. Samples outside of 3× median absolute deviations were deemed outliers and were excluded from the analysis.
Results
Microfluidic co-culture device to expose hippocampal synapses to synthetic or cell secreted Aβ oligomers With the goal to better mimic AD in vitro, we developed a microfluidic device that permits synapse formation between two sets of neurons cultured in distinct chambers. Based on a previous design, our device consists of three distinct chambers, interconnected via parallel microchannels that constrain neuronal cell bodies but permit axons and dendrites to cross through ( Fig. 1) (38) . Adjusting the lengths of microchannels made it possible to allow axons and dendrites from the right (or "postsynaptic") chamber, but only axons from the left (or "presynaptic") chamber to reach the central (or "synaptic") chamber (Fig. 1C) (30) . As a novel design feature, one end of the synaptic chamber bifurcates, where one branch terminates with an access well and the other one connects to a fourth (co-culture) chamber via a dense series of short microchannels. In addition, we employed narrowing microchannels that promote unidirectional neurite crossing (53) . When rat postnatal hippocampal neurons were cultured in one chamber only (Fig. S2 ), 2.9× more axons crossed the long microchannels in the forward direction (from the wide end towards the narrow end) than the reverse direction. This figure decreased to 1.9× in the case of short microchannels.
At 14 days in vitro (DIV14), no dendrites emanating from neurons cultured in the presynaptic chamber were observed in the synaptic chamber. Axons from these neurons, however, invaded the entire synaptic chamber. 11.0%±4.0% of these axons crossed the short microchannels in the reverse direction and reached the postsynaptic chamber, as measured by the ratio of the β3-tubulin fluorescence between the emitting and receiving chambers. On the other hand, axons and dendrites from neurons cultured in the postsynaptic chamber fully invaded the synaptic chamber by DIV14. None of these dendrites and only 5.9%±1.6% of these axons crossed the long microchannels in the reverse direction and reached the presynaptic chamber. Synapse formation in the synapse chamber was confirmed by immunostaining against Synaptophysin (Syp) 1 and Homer 1, pre-and postsynaptic markers, respectively (Fig. 1E ). In summary, the synaptic chamber receives axons from both pre-and postsynaptic chambers, receives dendrites only from the postsynaptic chamber, and contains 83.2%±6.1% of all synaptic connections formed between pre-and postsynaptic chambers.
Effect of synthetic Aβ 42 oligomers on synapse connectivity
We oligomerized synthetic Aβ 1-42 and Aβ 42-1 (inverted control peptide) and assessed the presence of oligomeric species via Coomassie blue staining. We confirmed the presence of low-MW oligomers in the Aβ 1-42 sample ( Fig. 2A ). We exposed mature synapses (DIV14) to synthetic Aβ peptides by adding the oligomer solution to the synapse chamber to reach an initial concentration of 100 nM. We kept the media levels in the synaptic reservoirs lower than those in the pre-and postsynaptic reservoirs. The hydrostatic pressure difference induced a flow through the microchannels countering the molecular diffusion, which localized the treatment initially to the synaptic chamber. However, as the pressure-driven flow ceased, the media levels equilibrated and Aβ peptides diffused throughout the device. Since the short microchannels offer little fluidic resistance compared to the long microchannels, it would be safe to assume that the media levels equilibrated first between the synaptic and postsynaptic chambers and then between the synaptic and presynaptic chambers. At the end of the 16 h treatment period, the neurons were fixed and immunostained against pre-and postsynaptic markers. To quantitatively analyze synaptic connectivity, we developed an image analysis workflow based on scanning confocal microscopy, software-assisted identification of pre-and postsynaptic puncta, and proximity-based assignment of postsynaptic puncta to presynaptic puncta (Fig. S1 ). Briefly, each Homer spot was assigned to the nearest Syp spot within a cut-off distance, which was pre-determined using a training set (Fig. S1G ). The fraction of Syp puncta with at least one Homer assignments and the average number of Homer assignments per Syp were determined to be the most robust read-outs of synapse connectivity. Exposing synapses to synthetic Aβ 1-42 oligomers decreased the fraction of assigned Syp without affecting the average number of assignments (Fig. 2B) . However, the effect size was small (15.6%) and the variation within and among experiments was high.
Co-culture with CHO cells expressing human APP with London mutation (V717I) induces synaptotoxicity
We cultured Chinese hamster ovary (CHO) cell lines stably overexpressing human APP, either wild-type (CHO-APP WT ) or with V717I (London) mutation (CHO-APP LDN ). It has been shown that CHO-APP WT and CHO-APP LDN continuously secrete physiologically-relevant forms of Aβ molecules and CHO-APP LDN provides toxic Aβ species (43) . Immunoblot analysis of media collected from CHO cell cultures confirmed that only the peptides secreted by CHO-APP LDN formed low-MW oligomers (Fig. 2C) . In contrast, CHO-pcDNA4 cells, which do not overexpress APP, did not produce any Aβ. We conducted off-chip ELISA measurements to determine the relative levels of Aβ species in CHO cell media (Fig. S3 ). As expected, treatment with the γ-secretase inhibitor DAPT completely blocked the secretion of Aβ peptides by both CHO-APP WT and CHO-APP LDN cells. Moreover, Aβ 1-42 (but not Aβ 1-40 ) levels in CHO-APP LDN media was higher than in CHO-APP WT media, further supporting the immunoblot results.
To determine the effect of CHO cell-secreted Aβ forms on synapses, we plated ca. 10,000 CHO cells in the co-culture chamber 4-6 days prior to the primary neuron culture. This timing was necessary to overcome the problems invoked by the differences of growth media composition between CHO cells and primary neurons. CHO cells proliferated in their growth medium and fully occupied the co-culture chamber. CHO cells were able to cross the short microchannels separating the co-culture chamber from the synaptic chamber (Fig. 1D ), but they did not migrate up the synaptic chamber. When the growth medium was replaced with the stimulation medium, the cells stopped proliferating, but continued to secrete Aβ peptides. To confirm that CHO cell-secreted Aβ forms diffused into the synaptic chamber, we collected media from different media reservoirs and quantified their Aβ 1-X and Aβ 1-42 peptide content using corresponding Alpha-LISA kits. Note that media collected from the wells of the microfluidic device did not contain sufficient material for immunoblotting. Measurements taken at DIV14 revealed that the ratio of Aβ 1-42 to other Aβ forms in the synaptic chamber was 4.4-fold higher in CHO-APP LDN co-cultures than in CHO-APP WT cocultures (Fig. 2D) , as expected for the overexpression of mutated APP (43) . Aβ forms in the media decreased to undetectable levels when CHO cells were treated with γ-secretase inhibitor DAPT for 5 d prior to media collection, further confirming that the majority of the measured Aβ in the synaptic chamber was secreted by the CHO cells. Presence of Aβ 1-X in media collected from the synaptic chamber, but not in the co-culture chamber of the CHO-pcDNA4 co-cultures is indicative of neuronal APP processing, since CHO-pcDNA4 cells do not express APP and therefore do not secrete Aβ peptides (Fig. S4) .
We conducted off-chip experiments to assess the availability of cell-secreted Aβ forms following the addition of the conditioned media to primary neuron cultures. Alpha-LISA measurements conducted at different time points (from 6 h to 7 d) suggested that Aβ concentrations in the media decreased logarithmically over time ( Fig. S5 ), suggesting that the peptides degraded or consumed by the cells. In contrast, the concentration of synthetic Aβ 1-42 peptide did not exhibit such a decrease over time when added to neurons (Fig. S6 ). These observations further support the idea that cell-secreted Aβ forms need to be periodically resupplied to the neuron culture medium unless a co-culture model is available. When synapses were exposed to CHO cell-secreted Aβ forms for 14 days in the co-culture device, a strong decrease in synapse connectivity was observed in CHO-APP LDN , but not in CHO-APP WT co-cultures ( Fig. 2E ). In this case, i.e., following chronic exposure, the effect size was large (48.9%) and the variation within and among experiments was low. The average number of Homer puncta assigned per Syp puncta was also significantly lower for CHO-APP LDN co-cultures (22.5% decrease compared to CHO-APP WT ).
Aβ antibody 3D6 alters the ratio between different Aβ forms and blocks CHO-APP LDN -induced synapse loss
To further characterize the CHO cell-secreted Aβ forms, we tested two monoclonal Aβ antibodies, human SAR228810 (8810; Sanofi; 3 μg/mL) and the mouse version of Bapineuzumab (3D6; Janssen; 3 μg/mL). Both antibodies were developed for passive immunotherapy and tested in clinical trials. 8810 antibody targets soluble protofibrillar and fibrillar species of Aβ and is inactive against Aβ monomers and small oligomeric aggregates (54) . In contrast, the 3D6 antibody targets the N-terminal region of Aβ and expected to capture Aβ molecules in the monomeric conformation (55, 56) .
We first conducted off-chip experiments where CHO cells were treated with these antibodies (or with 18 μg/mL DAPT as a negative control) for 5 d. Western blots of the conditioned media showed that DAPT treatment eliminated all Aβ secretion and induced a slight increase in the levels of APP (Fig. 3A) . However, WBs of conditioned media following DAPT treatment exhibited a 15 kDa band that overlapped with oligomers of low MW Aβ . Treatment with neither antibody affected the presence of low-MW Aβ 1-42 forms. Interestingly, the 3D6 antibody induced a strong increase in monomeric Aβ 1-42 levels in both CHO-APP WT and CHO-APP LDN media, in accordance with the idea that 3D6 arrests the peptide in monomeric form and precludes oligomer formation.
We next performed Alpha-LISA measurements from media collected from the co-culture chamber, following the treatment of CHO cells with the aforementioned antibodies for 5 d. However, the 3D6 antibody interfered with the Alpha-LISA measurements and could not be reported (no effect was observed for 8810 antibody). We therefore conducted off-chip ELISA measurements in the media of antibody-treated CHO cells. Treatment with either antibody increased Aβ 1-40 in both CHO-APP WT and CHO-APP LDN media. Treatment with 8810 antibody did not affect Aβ 1-42 concentration in CHO-APP LDN medium, but increased it in CHO-APP WT to the CHO-APP LDN level. In both CHO-APP WT and CHO-APP LDN media, 3D6 antibody treatment caused a decent increase in Aβ 1-40 , but a very large increase in Aβ 1-42 , consistent with the WB data (Fig. 3B) . In summary, the 3D6 antibody appears to arrest Aβ 1-42 peptides in monomeric form, thus leading the accumulation of the signal.
Finally, we analyzed synaptic connectivity in co-cultures treated with 8810 and 3D6 antibodies for 5 d prior to fixation (Fig. 3C ). Similar to Fig. 2E , untreated CHO-APP LDN co-cultures exhibited a strong (46.6%) decrease in the fraction of Syp puncta assigned by Homer puncta and a significant decrease (26.9%) in the number of Homer assignments per Syp. Treatment with 8810 antibody did not induce a significant difference relative to untreated controls in both cell types. However, treatment with 3D6 antibody completely blocked the effect of CHO-APP LDN on the fraction of Syp assigned and partially blocked the effect of CHO-APP LDN on the number of assignment per Syp. In summary, treatment with an antibody that prevents Aβ monomers from forming oligomers interfered with CHO-APP LDN -secreted Aβ species and protected synapses from toxicity likely induced by low-MW oligomers. These findings highlight the potential use of our disease-on-achip model and synaptic connectivity analysis for assessing the synapto-protective effects of therapeutic compounds for AD, such as Aβ-targeting antibodies.
Pyk2 overexpression in "postsynaptic" neurons blocks CHO-APP LDN -induced decrease in synapse connectivity
We next assessed the relevance of our microfluidic tool to establish whether genetic risk factors of AD may be involved in A-dependent synaptotoxicity. Several lines of evidence indicate that genetically driven synaptic failure may occur in AD (25) and among the different genetic risk factors susceptible to be studied in our model we focused on PTK2B which has been already described to be involved in synaptic functions (20) .
We evaluated potential changes in the expression of PTK2B in the brains of AD patients compared to healthy individuals by taking advantage of three publicly available RNAseq datasets: Mayo Clinic data that probed the temporal cortex (47) ; ROSMAP data that probed the dorsolateral prefrontal cortex (46) ; and the MSBB data that probed four different brain areas: BA 10, BA 22, BA 36, and BA 44 (45) . This allowed us to investigate potential gene expression changes in brain regions that are affected at different pathological stages of AD (57) . We observed a decrease in PTK2B expression in AD cases compared to healthy controls in all brain regions analyzed (Table S2) ; however, after multiple testing correction this decrease was significant only in the BA 22 (16.69% decrease; p adj = 1. 99×10 -02 ), BA 36 (28.89% decrease; p adj = 8.49×10 -05 ), and BA 44 (15.18% decrease; p adj = 3.87×10 -02 ) regions of the MSBB dataset, as well as in the ROSMAP dataset (28.89% decrease; p adj = 4.57×10 -03 ). Consistent with these results, we observed a decreasing trend in Pyk2 total protein levels and an increasing trend in the p-Pyk2 protein levels in the brains of AD patients compared to healthy controls (Fig. S7 ). These changes resulted in an increase in the relative phosphorylation of Pyk2 in the hippocampus (4.1-fold increase in the p-Pyk2:Pyk2 ratio; p = 0.0274; Wilcoxon rank sum test; 17 cases vs. 6 controls) and in the cortex (3.6-fold increase in the p-Pyk2:Pyk2 ratio; p = 0.0274; Wilcoxon rank sum test; 17 cases vs. 7 controls), suggesting a compensatory mechanism.
We then evaluated the levels of Pyk2 and phospho-Pyk2 in primary neurons as a function of A exposure. We conducted off-chip synaptosome extraction using primary cortical neurons treated with CHO cell media (Fig. 4B ). We observed total Pyk2 and p-Pyk2 in both non-PSD and PSD fractions. Syp and PSD95 signals were not different between neurons treated with CHO-APP WT medium and neurons treated with CHO-APP LDN medium (Fig. S9) ; however, CHO-APP LDN medium caused significant decreases in the relative amounts of total Pyk2 and p-Pyk2 in the postsynaptic fraction (Fig. 4B ).When p-Pyk2 (Tyr402) was immunostained alongside synaptic markers, we observed that signals localized to both pre-and postsynaptic puncta, with an increased tendency towards the latter (Fig. 4A ). We extended our distance-based synaptic connectivity analysis to quantitatively analyze the distribution of p-Pyk2 signals relative to identified synapses, i.e., Syp-Homer pairs. Our data showed that 1.5-fold more p-Pyk2 puncta were localized near postsynaptic puncta than near presynaptic puncta regardless of co-culture with CHO-APP WT or CHO-APP LDN cells (Fig. S8 ).
Since we observed (i) a decrease in PTK2B expression and a decreasing trend in Pyk2 protein levels in AD brains, (ii) a decrease in Pyk2 levels in the PSD fraction of cortical neurons upon treatment with CHO-APP LDN media, and (iii) a decrease in synaptic connectivity in hippocampal neurons upon co-culture with CHO-APP LDN cells, we hypothesized that Pyk2 was protective and its overexpression could rescue the detrimental effect of CHO-APP LDN co-culture on synapses. Since the active form of Pyk2 was strongly associated with postsynapses and CHO-APP LDN medium affected Pyk2 levels specifically in the PSD fraction, we decided to take advantage of microfluidic compartmentalization and modulate Pyk2 expression in postsynaptic neurons. To this end, we first verified the overexpression of Pyk2 off-chip via lentiviral transduction of the relevant shRNA or cDNA, respectively (Fig. S10 ). Next, by using lentiviruses expressing fluorescent proteins, we confirmed that the transduction was restricted to the target chamber (selectively to pre-or postsynaptic chambers; Fig. S11 ). Over-expression of Pyk2 in the postsynaptic chamber blocked the detrimental effect of CHO-APP LDN co-culture on synaptic connectivity, as evidenced by 12.9% decrease in the fraction of Syp puncta assigned by Homer puncta (as compared to 33.9% decrease when overexpressing the control vector; Fig. 4C ). As expected, synaptic connectivity in CHO-APP WT co-cultures was not affected by Pyk2 overexpression (8.7% increase in the fraction of Syp assigned by Homer), confirming that the synaptoprotective effect of postsynaptic Pyk2 overexpression was specific to Aβ toxicity due to CHO-APP LDN co-culture.
Discussion
The use of microfluidic culture devices for isolating synapses from neuronal cell bodies has been previously demonstrated (30, 31) . Our co-culture device combines two design concepts: First, by employing different microchannel lengths, it guarantees that dendrites from one but not the other neuron chamber can arrive to the synapse chamber. Second, it minimizes the penetration of axons from the synapse chamber to the neuron chambers. Our co-culture device facilitated the passage of axons in the intended direction: 2.9× and 1.9× more axons crossed the microchannels in the intended direction relative to the reverse direction, respectively for long and short microchannels. These ratios are indicative of a limited effect of the narrowing channel design on hippocampal neurons and are consistent with earlier reports (53) . Our co-culture device also facilitated the concentration of synapses in the synapse chamber: More than 83% of all synapses formed between neurons cultured in the pre-and postsynaptic chambers were found in the synapse chamber. It therefore provides a simple yet robust method to treat and analyze synapses independent of the cell bodies. It is important to note that while all dendrites in the synapse chamber arrive from the postsynaptic chamber, the opposite statement is not true, i.e., not all axons in the synapse chamber arrive from the presynaptic chamber. Thus, overexpressing Pyk2 in the postsynaptic chamber guarantees that, for all synapses analyzed, Pyk2 is overexpressed in the postsynaptic neuron (if we assume 100% transduction efficiency); however, it cannot be known whether or not Pyk2 is also overexpressed in the presynaptic neuron.
Several parameters can be considered when inducing Aβ-dependent synaptotoxicity: (i) use of synthetic versus organic oligomers; (ii) acute versus chronic treatment. Our microfludic co-culture model combines organic oligomers at physiological concentrations with chronic treatments and consistently induces Aβdependent synaptotoxicity. This is in agreement with a recent report that synthetic oligomers do not assume the same molecular structure as organic oligomers,(26) suggesting potential differences in their biological effects. Interestingly, as opposed to synthetic Aβ oligomers, organic Aβ appears to be degraded in our primary neuronal cultures, further highlighting the difference in bioavailability between the two. This observation also indicates that the co-culture model is better adapted for synaptotoxicity studies since it maintains physiological concentrations thanks to the constant release of Aβ peptides from CHO cells. This allows for the analysis of synapse connectivity in response to chronic exposure of synapses to organic Aβ oligomers, as opposed to acute exposure to conditioned media, for instance.
It is important to note that the Aβ peptides secreted by the CHO-APP LDN cells do diffuse into the various chambers of the microfluidic device, considering the long duration of co-culture experiments. Thus, the synaptic toxicity observed may not be due to a local effect on synapses, but originate from Aβ's toxic effect on neuronal cell bodies. If true, this is more likely due to toxicity on neurons in the postsynaptic neurons, as the fluidic barrier between the synaptic and postsynaptic chambers is much weaker than that between the synaptic and presynaptic chambers. Regardless of this possibility, our results do not allow us to propose a specific mechanism for the observed Aβ-induced synaptotoxicity.
The role of Pyk2 in synapses appears to be complex, considering the seemingly opposite results of recent studies: Pyk2 has been shown to be required for long-term potentiation (LTP) (28) . However, others have shown that Pyk2 is not required for LTP, but for long-term depression (23, 58) , and Pyk2 overexpression inhibits LTP (58) . The role of Pyk2 in Aβ toxicity has also been debated, where it has been shown to be deleterious (23) or protective (29) in mouse models. Our findings are in agreement with the notion that Pyk2 localizes to the postsynaptic compartment (20) . At the AD pathophysiological level, several of our observations fit well with the results of a recent in vivo study using AD-like mouse models: (i) decreased Pyk2 activity has been reported in 5XFAD mice (29) , although Pyk2 has also been shown to be activated in acute Aβ oligomer treatment on brain slices (59, 60); (ii) rescue of Pyk2 expression improved the behavioral and synaptic molecular phenotypes of the double transgenic 5XFAD×Pyk -/mouse model (29) . Interestingly, this rescue seems to have no impact on Aβ loads, suggesting that Pyk2 overexpression impacts pathophysiological processes downstream of Aβ production and amyloid deposition. This observation is in agreement with our results suggesting that Pyk2 overexpression may restrict Aβ-induced synaptotoxicity.
Nevertheless, it is important to mention that the sparse literature on Pyk2's role in synapses is highly dependent on the model and calls for further in vitro and in vivo work.
Conclusions
In conclusion, our microfluidic co-culture device provides an in vitro model of Aβ synaptotoxicity based on exposing synapses of primary hippocampal neurons to cell-secreted Aβ peptides. This disease-on-a-chip model is highly relevant to AD in several aspects: (i) long-term, low-dose exposure to organic Aβ forms is preferable over acute treatments with synthetic oligomers at high concentrations; (ii) isolating synapses in a separate microfluidic chamber facilitates the analysis of synaptic connectivity via immunostaining pre-and postsynaptic markers without the interference of cell bodies; (iii) providing exclusive access to pre-and postsynaptic neurons to selectively under-or overexpress AD genetic risk factors therein helps dissect their potential roles in pre-and postsynaptic compartments. Deciphering the mechanisms by which the genetic risk factors contribute to AD pathology will help develop targeted therapies based on genetic information.
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Figure S11
. Demonstration of isolated lentiviral treatments at DIV14. Cells cultured in pre-and postsynaptic chambers were transducted at DIV7 with lentiviruses to express LifeAct-ruby (red) and LifeAct-GFP (green), respectively.
